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Bacterial lower respiratory tract infections (BLRTI) may represent serious clinical conditions which 
can lead to respiratory failure, ICU admission and high hospital costs. The detection of 
carbapenemase- and extended-spectrum β-lactamase (ESBL)-producing Enterobacterales, as well 
as methicillin-resistant Staphylococcus aureus (MRSA), has become a major issue especially in 
health care associated infections. This study aimed to etermine whether molecular assays could 
detect genes encoding carbapenemases, ESBL and MRSA, directly from respiratory samples, so as 
to expedite appropriate therapy and infection control for patients with BLRTI. 
Methods 
The CRE, ESBL and MRSA/SA ELITe MGB® assays were performed directly on 354 respiratory 
specimens sampled from 318 patients admitted with BLRTI. Molecular results were compared to 
routine culture-based diagnostics results. 
Results 
Positive (PPV) and negative (NPV) predictive values of the CRE ELITe MGB® kit were 75.9% [IC 
95%: 60.3-86.7] and 100%, respectively. PPV and NPV of the ESBL ELITe MGB® kit were 80.8% 
[IC 95%: 63.6-91] and 99.1% [IC 95%: 96.6-99.8], resp ctively. PPV and NPV predictive values of 
the MRSA/SA ELITe MGB® kit were 91.7% [IC 95%: 73.7-97.7]/100% and 98.3% [IC 95%: 89.8-
99.3]/96.8% [IC 95%: 81.6-99.5], respectively. 
Discussion 
Validity assessment of molecular assays detecting the main antibiotic resistance genes directly from 
respiratory samples showed a high accuracy when compared to culture-based results. Molecular 
assays detecting the main carbapenemase, ESBL, . aureus and methicillin resistance encoding 
genes provide an interesting tool with potential to expedite optimization of antibiotic therapy and 
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Bacterial lower respiratory tract infections (BLRTI) including bronchitis, pneumonia, as well as 
infectious exacerbations in chronic lung disease can represent serious clinical conditions which can 
lead to respiratory failure, ICU admission, prolonged admissions and high hospital costs [1-7]. 
Patients admitted with BLRTI are frequently prescribed broad-spectrum empirical antibiotics; 
timely pathogen identification is necessary to support antibiotic stewardship and therefore reduce 
the risk of selection of antibiotic resistance. Detection of carbapenemase- and extended-spectrum β-
lactamase (ESBL)-producing Enterobacterales (EB) and methicillin-resistant Staphylococcus 
aureus (MRSA) has important implicatons fot both antimicrobial therapy and infection control, 
especially in health care associated infections. 
A positive microbiological diagnosis in BLRTI may only be made in approximately 30% of cases 
[8] and, since commensal and colonizing microorganisms complicate the analysis, conventional 
phenotypic diagnostics for respiratory samples typically takes around 48–72, hampering 
antimicrobial stewardship. Molecular tests for genes encoding carbapenemases, ESBLs and MRSA 
have been successfully applied directly to blood culture samples [9,10] but there is limited 
published evidence about their performance on respiratory samples [11-15]. 
The ELITe InGenius® (ELITechGroup Molecular Diagnostics, Turin, Italy) platform is an integrated 
system that automatically performs nucleic acid extraction, real-time PCR, and interpretation of 
results in less than 3 h. The CRE and ESBL ELITe MGB® kits are qualitative multiplex real-time 
PCR assays for the detection of the most prevalent carbapenemase and ESBL encoding genes in 
EB. The CRE ELITe MGB® Kit detects blaKPC-like, metallo β-lactamase (i.e. blaNDM-like, blaVIM-like , 
blaIMP-like), and blaOXA-48-like genes; the ESBL ELITe MGB
® kit detects blaCTX-Ms genes belonging to 
groups 1 (including CTX-M-15) and 9 (including CTX-M 14). The MRSA/SA ELITe MGB® kit is 
a multiplex assay that simultaneously detects a conserved sequence of the S. aureus, mecA gene and 
its homologue mecALGA251 (mecC).  
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The aim of this study was to evaluate the performance of CRE, ESBL and MRSA/SA ELITe MGB® 
assays directly on respiratory samples, including comparing real-time PCR cycle threshold (Ct) 
values with bacterial load quantification. 
 
Methods 
Routine culture-based microbiological diagnostics 
At the Microbiology and Virology Unit of “Azienda Ospedaliero-Universitaria Città della Salute e 
della Scienza di Torino” (Turin, Italy) respiratory samples were subjected to Gram staining and 
culture on appropriate solid medium at the time of arrival to the lab. MALDI-TOF MS analysis was 
used for bacterial identification and antimicrobial susceptibility testing was carried out on overnight 
subcultures using Microscan WalkAway plus System (Beckman Coulter, Brea, CA, USA) according 
to the manufacturer's instructions. Antimicrobial susceptibilities were interpreted according to 
EUCAST breakpoints as updated in 2019 [16]. The Total ESBL Confirm kit (Rosco, Taastrup, 
Denmark) was used to identify ESBL production if ceotaxime (CTX) and/or ceftazidime (CAZ) 
minimal inhibitory concentrations (MICs) were > 1 mg/l. The Mastdiscs® combi Carba plus disc 
system (Mast Group Ltd, Bootle, UK) was used to asses  carbapenemase producers when 
meropenem (MP) MIC was > 0.125 mg/l. Detection of carbapenem resistance genes was performed 
using the Xpert Carba-R assay (Cepheid, Sunnyvale, CA, USA). 
 
Specimen collection and study design 
Respiratory samples included in the study were those submitted for standard of care bacterial 
culture from January to June 2019. They were selected randomly based on sample type, integrity 
and amount of remnant specimen. Lower respiratory tract specimens included: sputum, tracheal 
aspirate (TA), bronchoaspirate (BA) and bronchoalveolar lavage (BAL). The administration of 
antibiotics before specimen collection was not assessed. 
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The ELITe MGB® assays were performed directly on 354 respiratory specimens sampled from 318 
patients. The CRE and ESBL ELITe MGB® kits were assayed on sputum (n=7), TA (n=16), BA 
(n=16) and BAL (n=202), and the MRSA/SA ELITe MGB® kit was tested on sputum (n=35), TA 
(n=25), BA (n=15) and BAL (n=38). Two-hundred µl previously heated in a thermoblock at 90ºC 
for 5 minutes of a 1:4 dilution in dithiothreitol solution (Sputasol, Oxoid Ltd, Basingstoke, United 
Kingdom) were used for sputum, TA and BA, whereas 200 µl of a 1:2 dilution in dithiothreitol 
solution were used for BAL. The ELITe MGB® kits internal control and positive and negative 
controls were used as previously described [10].  Total ELITe MGB assay test run time is 2 h 12 
min with data analysis available immediately after the run. ELITe MGB® assays total cost includes 
reagents (approximately £25 per sample including DNA extraction), staff time and platform ELITe 
InGenius® rental. 
Molecular results were then compared to routine culture-based microbiological diagnostics results 
to estimate the accuracy of genotypic analysis. Molecular results for the CRE, ESBL and MRSA/SA 
targets were interpreted as shown in Table 1. All cycles with a Ct value > 35 were considered 
negative for detectable signal. Presence of S. aureus and mecA/C targets at the same relative 
quantity (∆Ct between the two targets < 2) was considered indicative of MRSA (to mitigate against 
the potential for detection of meticillin-susceptible S. aureus together with meticillin-resistant 
coagulase-negative staphylococci. 
Ct values were also compared to the quantitative culture results in order to maximize the potential 
clinical impact of molecular results. 
This study was conducted in accordance with the Declaration of Helsinki. Formal ethical approval 
was not required by our Centre’s institutional review board since the samples were anonymized and 





Accuracy, sensitivity, specificity, positive (PPV) and negative (NPV) predictive values of the CRE, 
ESBL and MRSA/SA ELITe MGB® kits with 95% confidence interval (CI 95%) were computed. 
The Shapiro-Wilk test was performed to verify the normality of distribution of quantitative 
variables.  Analysis of variance (ANOVA) with Bonferroni correction was carried out to assess 
whether significant differences in Ct values could be detected among quantitative culture groups 
(negative; 1,000-10,000 CFU/ml; >25,000 CFU/ml for carbapenemase- and ESBL-producers EB; 
negative; 1,000-10,000 CFU/ml; 10,000-50,000 CFU/ml; >50,000 CFU/ml for S. aureus). 
p values of less than 5% were considered significant. 
All analyses were performed with Stata 14.
 
Results 
Detection of carbapenemase, CTX-M and S. aureus and mecA/C genes 
Table 2 shows the comparison between molecular and co ventional phenotypic results. 
Among the 241 clinical specimens, blaKPC-like was detected in 29 (12%) specimens by the CRE 
ELITe MGB® kit. Twenty-two (75.9%) of these samples were confirmed by culture. Five of the 7 
false-positive samples were from patients who becam culture-positive for KPC-producing K. 
pneumoniae (TA n=2; BA n=1; urine culture n=1; rectal swab n=1) in the subsequent 7 days. blaCTX-
M-like was detected in 26 (10.8%) specimens by the ESBL ELITe MGB
® kit, of which 21 (80.8%) 
were confirmed by culture. Two of the 5 false-positive samples were from patients who ESBL-
producing K. pneumoniae (blood culture n=1; urine culture n=1) isolated in the subsequent 7 days. 
The corresponding cultures of the two false-negative samples grew ESBL-producing K. 
pneumoniae and ESBL-producing K. oxytoca at quantities of 25,000-50,000 CFU/ml. No other 






ELITe MGB® kit detected S. aureus in 82/113 (72.6%) specimens, all of which were confirmed by 
culture. There was one false-negative sample, which gave a Ct value of 38.2, and a semi-
quantitative culture result of 10,000-50,000 CFU/ml. Among the 83 culture-positive S. aureus 
samples, the mecA/C target was found in 23. The two presumed false positive samples by PCR may 
reflect the limitations of meticillin resistance phenotypic detection [17] or the presence of mixed 
populations of bacteria. The false negative sample showed ∆Ct=2.61 and culture-based diagnostics 
showed a mixed population of MRSA and methicillin resistant CoNS. 
The Ct values determined by CRE, ESBL and MRSA/SA ELITe MGB® kits were compared to the 
bacterial loads obtained by conventional culture-based approach, (see supplementary material, 
Figure 1 and 2). The mean Cts obtained by CRE, ESBL ELITe MGB® kits were significantly 
different (p<0.05) between culture negative and >25,000 CFU/ml groups. With the MRSA/SA 
ELITe MGB® kit mean Cts between each quantitative culture group were found significantly 
different (p<0.05) except between groups of 1,000-1,000 CFU/ml and 10,000-50,000 CFU/ml. 
 
Discussion 
Conventional culture-based diagnostics has limitations in tackling the dissemination of multidrug 
resistant pathogens and in optimizing antibiotic therapy in patients with BLRTI in a timely manner. 
Molecular assays have the potential to perform a role as a more accurate and sensitive decision-
making tool expediting infection control practices and supporting efforts to curtail inappropriate 
antibiotic use [12, 18-19].  
This study represents one of the largest performance ssessments of molecular assays detecting the 
main antibiotic resistance genes directly from clini al respiratory samples. High negative predictive 
values, but more variable positive predictive values were found. Several molecular assays of 
microbiological respiratory diagnostics focused on rapid pathogen identification but few data on 
rapid antibiotic resistance have been reported, other t an for MRSA [15, 20-22]. The CRE and 
ESBL ELITe MGB® kits were particularly suited for the Italian and European epidemiology, since 
9 
 
the selection of these samples represents a picture of th  most prevalent carbapenemase- and ESBL- 
EB [23]. However, limited number of enzymes tested for would need to be considered if these tests 
were implemented into clinical practice. Our data indicate that the MRSA/SA ELITe MGB® kit, 
when S. aureus and mec genes are detected at the same relative quantities in the presence of clinical 
signs of BLRTI could be of value in guiding the need for anti-MRSA therapy.  
The potential role of molecular assays in surveillance, infection control practices and early 
optimization of antibiotic therapy is well known [12,24,25]. In particular, rapid availability of 
molecular results can not only facilitate early appro riate antibiotic therapy for patients with 
multidrug resistant (MDR) bacterial infection, but can also guide earlier de-escalation of antibiotic 
therapy for patients with negative results. Accuracy rates of the ELITe MGB® assays confirm that 
molecular approach together with the knowledge of local epidemiology susceptibility patterns could 
be used to expedite optimization of empirical antibio c therapy and infection control practices in 
patients with BLRTI, especially when providing positive results for targeted antibiotic resistance 
genes. However, conventional culture-based antimicrob al susceptibility testing continues to be 
required both to confirm molecular results and to detect other antibiotic resistance mechanisms. 
Nucleic acid amplification techniques cannot distinguish between living and dead bacteria [26]. The 
degree of correlation between bacterial load and Ct values could be conditional on factors affecting 
the viability of bacteria at the time of sampling (prior antibiotic treatment, immune-mediated 
bacterial death [27]), as well as potentially the pr sence of multiple copies of the same gene on 
mobile genetic elements [28,29]. In spite of these limitations, this study showed how Ct analysis 
may deliver some information about bacterial load. 
 
Our study has several limitations, the main one being the lack of clinical data and prospective 
assessment of direct implications of molecular results on antimicrobial stewardship and clinical 
outcome. The administration of antibiotics before sampling was not known and this factor might 
have hampered the overall evaluation of the molecular false positive results. Nevertheless, we 
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believe that this study does show the potential for the use of CRE, ESBL and MRSA/SA ELITe 
MGB® kits to support infection control and antibiotic stewardship programmes in patients with a 
high suspicion of MDR BLRTI infection. Any future studies of the effectiveness of this approach 
will need to consider the feasibility of producing results in a timely manner (testing requires around 
30 minutes of laboratory hands-on time and a test run time of around 3 hours), as well as the 
willingness of clinicians to respond to the results. All of these results would in turn have to feed into 
an assessment of the cost-effectiveness. 
 
Conclusions 
In the smart era of resistance profiling the ELITe MGB® assays showed reasonable accuracy for the 
detection of carbapenemase- and ESBL-producing EB and MRSA in respiratory samples. These 
tests might be a useful complementary tool for expediting optimization of empirical antibiotic 
therapy and infection control practices in patients with BLRTI, depending on local prevalences of 
antibiotic resistance. However, further studies are required to confirm our results, to determine 
robust Ct cut-off values for colonization vs. infection, and to determine their clinical and cost 
effectiveness in routine clinical practice are required. 
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Table 1. Interpretation of molecular results on respiratory samples for the detection of 
carbapenemase, ESBL, Staphylococcus aureus and meticillin resistance encoding genes. 
  Interpretation Report 
CRE  ELITe 
MGB ® Kit 
ESBL  ELITe 
MGB ® Kit 
  
+ - Carbapenemase encoding gene KPC, NDM-IMP-VIM, OXA-48 DNA 
detected 
+ + Carbapenemase and ESBL encoding genes Both KPC, NDM-IMP-VIM, OXA-48 
DNA detected and CTX-Ms DNA detected 
- + ESBL encoding gene CTX-M DNA detected 
- - Nor carbapenemase neither ESBL encoding 
genes 
Neither KPC, NDM-IMP-VIM, OXA-48 
nor CTX-Ms DNA detected 
    MRSA/SA ELITe MGB ® Kit  
S. aureus mecA/C   
+ + ∆Ct < 2, MRSA MRSA DNA detected 
+ + ∆Ct > 2, MSSA MSSA DNA detected 
+ - MSSA MSSA DNA detected 
- + No S. aureus No S. aureus DNA detected 
- - No S. aureus No S. aureus DNA detected 
All cycles with a cycle threshold (Ct) value > 35 were considered negative; 

















Table 2. Performance of the CRE, ESBL, MRSA/SA ELITe MGB kits on respiratory samples 





     
 Respiratory samples 
n=241 
     
 Positive Negative      





PPV        
[CI 95%] 
NPV        
[CI 95%] 
blaKPC-like 
Positive 22 7 
97.1% 







Negative 0 212 
blaCTX-M-like 













     
 Positive Negative      





PPV        
[CI 95%] 
NPV        
[CI 95%] 
S. aureus 








[81.6-99.5] Negative 1 30 
mecA/C 
Positive 22 2 
96.4% 
95.7%     
[79-99.2] 




98.3%     
[89.8-99.3] Negative 1 58 
PPV – positive predictive value; NPV – negative predictive value. 
